Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Veliparib (Primary)
- Indications Cancer
- Focus Biomarker; Therapeutic Use
- Acronyms REPAIR
- 13 Nov 2017 Planned initiation date changed from 1 Aug 2017 to 1 May 2018.
- 01 Jun 2017 Planned End Date changed from 1 Mar 2020 to 1 Aug 2020.
- 01 Jun 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2020.